Harmony Biosciences Holdings, Inc. announced that Jeffrey M. Dayno, M.D., has been appointed President by the Company's Board of Directors and has been elected to join as a member of the Board. Dr. Dayno joined Harmony as Chief Medical Officer and Executive Vice President when the company was founded in 2017 and has been serving as Interim President and CEO since January 6, 2023. Harmony Board Chairman, Jeff Aronin, noted that Dr. Dayno, a nationally recognized neuroscience expert, has been a valuable member of the Company's inaugural executive management team since 2017.

He played a critical role in the FDA approval of Harmony's key asset, WAKIX® (pitolisant), and helped to shape commercial strategy. With the appointment, Mr. Aronin returns to serving as non-executive Chairman of the Board. Dr. Dayno expressed appreciation for the Board's confidence in his leadership.